Will NSCLC targeted therapy extend my brother’s life at 39?

Question

Hello doctor,

My brother is 39 years old and was diagnosed with stage 4 non-small cell lung cancer (NSCLC) about six years ago. At the time of diagnosis, scans showed spread beyond the lungs, and we were told that the disease was advanced.

However, molecular testing revealed a specific mutation, and he was started on targeted therapy medication. Since then, his follow-up scans have shown stable disease with only minor changes, and he has been able to continue working and maintain his usual lifestyle with manageable side effects. Please tell me,

How is it possible for some patients with stage 4 lung cancer to live for many years on targeted therapy?
What factors contribute to such long-term control of the disease?

Kindly help.

Answer 1

Hello,

Welcome to icliniq.com.

I read your query and can understand your concern.

What you are describing is something we now see more frequently in patients whose lung cancer carries a specific genetic mutation. In these situations, the cancer often depends on one main molecular pathway to grow. Targeted therapy medicines are designed to block that exact pathway. When this signal is effectively blocked, the cancer cells lose the stimulus that drives their growth, so the disease can remain controlled for a long time.

Because of this, some patients with stage 4 lung cancer can live for many years with a good quality of life while taking targeted therapy. The treatment may not completely remove the cancer, but it can keep the disease stable for prolonged periods. In clinical practice, I have followed patients who continued their normal routines and work for several years while their scans showed only minimal changes.

Several factors influence how long your brother’s disease remains controlled.

One important factor is the presence of a clear driver mutation, because these tumors often respond well to targeted medicines.
Another factor is how well your brother tolerates the medication and can continue treatment regularly.
The biological behavior of the tumor also plays a role, as some cancers grow more slowly once the key growth pathway is blocked.

Your brother’s experience reflects how much treatment for lung cancer has improved in recent years. With appropriate molecular testing and targeted therapy, some patients with advanced disease can maintain long-term control and continue their usual activities.

I hope this information helps you.

Feel free to ask further queries.

Thank you.